IGF2BP3 and breast cancer: Taken together, the present study on METTL3/IGF2BP3-mediated N6-methyladenosine modification of PD-L1 mRNA and antitumor immunity provided a novel mechanism for m6A regulator-induced immunosuppression in breast cancer, which may have potential application as a novel therapeutic target.